Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system.
Ontology highlight
ABSTRACT: Cancer gene therapy has attracted increasing attention for its advantages over conventional therapy in specific killing of tumor cells. Here, we attempt to prove a novel therapeutic approach that targets tumors by harnessing the blood antigen immune response system, which is inherently present in patients with breast cancers. Breast cancer MDA-MB-231 cells expressed blood group H antigen precursor. After ectopic expression of blood group A glycosyltransferase, we found that the H precursor was converted into the group A antigen, appearing on the surface of tumor cells. Incubation with group B plasma from breast cancer patients activated the antigen-antibody-complement cascade and triggered tumor cell killing. Interestingly, expression of blood A antigen also reduced tumorigenesis in breast
SUBMITTER: Han W
PROVIDER: S-EPMC5362465 | biostudies-literature | 2017 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA